AMRI opens research facility in Budapest
US drug discovery company AMRI (Albany Molecular Research Inc) has completed a new state-of-the-art chemistry r&d facility in Budapest, Hungary.
US drug discovery company AMRI (Albany Molecular Research Inc) has completed a new state-of-the-art chemistry r&d facility in Budapest, Hungary.
The company says the move into 3,000m2 of laboratory and administrative space marks a significant milestone in its plan to transform its European hub into a higher-value discovery services business through consolidation of multiple locations, equipment and operating costs.
As well as more efficient operations and enhanced technology transfer, the new site provides capacity for the anticipated expansion of synthetic chemistry services, currently projected to double over the next five years.
The mix of services has been expanded to include parallel synthesis and medicinal chemistry, as well as the establishment of fragment-based drug discovery. Also included is a scale-up laboratory for non-GMP synthesis for batch sizes up to 25 litres.
"Critical to the decision to undertake this project was the company's drive to cultivate a customer base relatively untapped," said AMRI chairman and chief executive Thomas D'Ambra. "We believe this latest investment, along with our parallel investments in the US, India and Singapore, will further strengthen AMRI's presence as a premier provider of a broad range of scientific services, capabilities and geographic choices around the globe."